Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
Cyramza | Ramucirumab | Cancelled | ||||
Keytruda | Pembrolizumab | classical Hodgkin Lymphoma (cHL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Spinraza | nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
Procysbi | cysteamine bitartrate | Nephropathic cystinosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Lartruvo | Olaratumab | Advanced Soft Tissue Sarcoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Actemra | tocilizumab | Giant cell arteritis (GCA) | Reimburse with clinical criteria and/or conditions | Complete |